Celularity acquires Rebound placental matrix product from Sequence LifeScience for $5.5M

Celularity Inc

Total consideration $5.5M: $1M upfront cash, up to $4M monthly milestone payments (20% of net sales), and $500K credit.
Exclusive supply agreement with Sequence for min 6 months; Celularity intends to transfer manufacturing in-house.
H1 2024 biomaterial sales >$24M, exceeding full year 2023; Rebound expected to contribute in Q4 2024.
Rebound is full-thickness placental-derived allograft matrix for wound care and soft tissue repair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.